Iovance Biotherapeutics (IOVA) Change in Account Payables (2016 - 2026)
Iovance Biotherapeutics (IOVA) posted quarterly Change in Account Payables of $15.9 million for Q1 2026, up 674.27% year-over-year from $2.1 million in Q1 2025, and up 404.78% quarter-over-quarter from -$5.2 million in Q4 2025.
Powered by 
Analysis
Iovance Biotherapeutics (IOVA) Change in Account Payables (2016 - 2026) Analysis & Trends
Iovance Biotherapeutics (IOVA) has reported Change in Account Payables for 11 consecutive years, with $15.9 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Change in Account Payables rose 674.27% year-over-year to $15.9 million; the TTM figure through Mar 2026 stood at $7.2 million (up 27496.15% YoY), while the FY2025 annual figure was -$6.7 million, up 15.05% from the prior year.
- Change in Account Payables rose to $15.9 million in Q1 2026 per IOVA's latest filing, from -$5.2 million in the prior quarter.
- Across five years, Change in Account Payables topped out at $15.9 million in Q1 2026 and bottomed at -$10.4 million in Q2 2024.
- Historically, Change in Account Payables has averaged $711588.2 across 5 years, with a median of $893000.0 in 2025.
- Annual changes were most pronounced in 2022 — Change in Account Payables sank 13926.67% — and 2026, when it jumped 674.27%.
- Iovance Biotherapeutics' Change in Account Payables stood at $1.6 million in 2022, then surged by 634.13% to $11.4 million in 2023, then slumped by 153.16% to -$6.1 million in 2024, then climbed by 14.15% to -$5.2 million in 2025, then surged by 404.78% to $15.9 million in 2026.
- Business Quant data shows IOVA's Change in Account Payables at $15.9 million in Q1 2026, -$5.2 million in Q4 2025, and -$4.4 million in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Account Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | -66.70 Mn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | -8.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | 5.03 Mn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 37.53 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | - |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | - |
| 10 | Iovance Biotherapeutics | 3.95 Bn | 3.66 Bn | 55.72 Mn | -11.82 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -11.82 Mn |
| Mar 31, 2026 | 15.89 Mn |
| Dec 31, 2025 | -5.21 Mn |
| Sep 30, 2025 | -4.39 Mn |
| Jun 30, 2025 | 893,000.00 |
| Mar 31, 2025 | 2.05 Mn |
| Dec 31, 2024 | -6.07 Mn |
| Sep 30, 2024 | 14.44 Mn |
| Jun 30, 2024 | -10.39 Mn |
| Mar 31, 2024 | -5.82 Mn |
| Dec 31, 2023 | 11.42 Mn |
| Sep 30, 2023 | -9.77 Mn |
| Jun 30, 2023 | 146,000.00 |
| Mar 31, 2023 | 3.03 Mn |
| Dec 31, 2022 | 1.56 Mn |
| Sep 30, 2022 | 4.26 Mn |
| Jun 30, 2022 | 2.17 Mn |
| Mar 31, 2022 | -2.10 Mn |
| Dec 31, 2021 | 7.72 Mn |
| Sep 30, 2021 | -5.69 Mn |